TCT’s late-breakers cover gamut in interventional care

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - Gregg Stone
Gregg W. Stone, MD
Source: Cardiovascular Research Foundation

The annual Transcatheter Cardiovascular Therapeutics (TCT) conference, scheduled Oct. 22-26 in Miami, will include a variety of presentations for interventional cardiologists, including the latest findings on pharmaceuticals, devices and imaging, according to TCT co-director Gregg W. Stone, MD, professor of medicine at Columbia University College of Physicians and Surgeons. 

Sponsored by the Cardiovascular Research Foundation and the American College of Cardiology, TCT.12 is expected to draw 12,000 attendees from 70 countries, Stone said in a media call previewing the event. In fact, the international presence will be quite strong, with 70 percent of attendees coming from outside the U.S.

TCT.12 will feature more than 750 abstracts, 400 to 450 presentations of challenging cases, results from late-breaking clinical trials and deep dives, which are several-hour sessions covering discrete aspects of interventional cardiology practice. The deep dive on Oct. 24 will focus on stroke prevention therapies; on Oct. 25, hypertension and renal artery denervation; and on Oct. 26, the RESPECT and PC trials.

"The blockbuster for this conference is the deep dive into the RESPECT and PC trials, with real implications for the debate about PFO [patent foramen ovale] closure for stroke," Stone said. 

The Cardiovascular Business editorial team will provide comprehensive coverage of the scientific sessions.

The late breaking trials and the dates they will be presented are:

Wednesday, Oct. 24

FAME II Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR (fractional flow reserve-Guided PCI in Patients with Stable Coronary Artery Disease. FAME II was designed to further study the role of FFR in the treatment of stable coronary artery disease by comparing PCI guided by FFR plus optimal medical therapy (OMT) to OMT alone.

MASTER: A Prospective, Randomized Trial of a PET Micronet Mesh-Covered Stent vs. Standard Stents in Patients with STEMI. 

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease.

PARTNER Cohort B Three Year: Clinical and Echocardiographic Outcomes from a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement in "Inoperable" Patients. This is the first presentation of long-term data from the PARTNER study, Stone said.

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After Coronary Angiography. TRILOGY ACS has shown that Prasugrel (Effient) was not superior to clopidogrel (Plavix) for reducing the rate of major cardiovascular events in patients with acute coronary syndrome (ACS) who do not undergo revascularization.

A Prospective, Randomized Trial of Nitinol Stents vs. Balloon Angioplasty in Obstructive Popliteal Lesions.

Thursday, Oct. 25

RESPECT: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Stroke.

The PC Trial: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Embolism.

A Prospective, Randomized Trial of Sliding-Scale Hydration for Prevention of Contrast Nephropathy.

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel Hyporesponsiveness on Patient Outcomes

AIDA STEMI MRI: Cardiac MRI Substudy from a Prospective, Randomized Trial of Intracoronary Abciximab in Patients with STEMI.

A Prospective, Randomized Trial of Post-Conditioning in Patients with STEMI.

Friday, Oct. 26

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents (EES) vs. Bare-Metal Stents in Octogenarians. This study is significant because it has not been known whether EES is beneficial in older patients, Stone said.

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of "Limus"-Eluting Coronary Stents.

STEMI-RADIAL: A Prospective, Randomized Trial of Radial vs. Femoral Access in Patients with ST-Segment Elevation Myocardial Infarction.